US Stock MarketDetailed Quotes
NMRA Neumora Therapeutics
- 2.170
- +0.200+10.15%
Close Jan 3 16:00 ET
- 2.170
- +0.000+0.01%
Post 19:59 ET
350.59MMarket Cap1.95P/E (TTM)
2.480High2.150Low22.81MVolume2.230Open1.970Pre Close51.16MTurnover26.86%Turnover RatioLossP/E (Static)161.56MShares21.00052wk High1.09P/B184.28MFloat Cap1.83052wk Low--Dividend TTM84.92MShs Float21.000Historical High--Div YieldTTM16.75%Amplitude1.830Historical Low2.243Avg Price1Lot Size
Neumora Therapeutics Stock Forum
Sign in to post a comment
$Neumora Therapeutics (NMRA.US)$
H.C. Wainwright reaffirmed its Buy rating and a price target of $30.00 for Neumora Therapeutics (NASDAQ:NMRA) stock.
——-
On Friday, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating on Neumora Therapeutics (NASDAQ:NMRA) with a steady price target of $20.00, despite the company's recent setback with its lead drug candidate, navacaprant.
———-
jp morgan target price 15
H.C. Wainwright reaffirmed its Buy rating and a price target of $30.00 for Neumora Therapeutics (NASDAQ:NMRA) stock.
——-
On Friday, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating on Neumora Therapeutics (NASDAQ:NMRA) with a steady price target of $20.00, despite the company's recent setback with its lead drug candidate, navacaprant.
———-
jp morgan target price 15
1
3
$Neumora Therapeutics (NMRA.US)$ target price $30.. time to buy before regret.
6
19
$Neumora Therapeutics (NMRA.US)$Neumora Therapeutics Selloff Seen as Overdone -- Market Talk
Many antidepressants have had at least one Phase 3 failure before winning approval
Many antidepressants have had at least one Phase 3 failure before winning approval
4
$Neumora Therapeutics (NMRA.US)$ drop again?
2
$Neumora Therapeutics (NMRA.US)$ PT 30... Still thinking?
1
2
NOTE!
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and educ...
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and educ...
78
34
20
$Neumora Therapeutics (NMRA.US)$ Pre-Market Updates
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not show a statistically significant improvement in the primary endpoint of change in MADRS score at Week 6 or the key secondary endpoint of SHAPS score. The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing.
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not show a statistically significant improvement in the primary endpoint of change in MADRS score at Week 6 or the key secondary endpoint of SHAPS score. The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing.
1
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Neumora Therapeutics (NMRA.US)$ Nmra Study Did Not Demonstrate Statistically Significant Improvement On Primary Endpoint Of Reduction In Depressive Symptoms As Measured By MADRS Total Score Compared To Placebo
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
LanceC : bye![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")